(ROG) Roche Holding - Ratings and Ratios
Pharmaceuticals, Diagnostics, Digital Health
Description: ROG Roche Holding
Roche Holding AG is a multinational healthcare company operating in the pharmaceuticals and diagnostics sectors globally, with a presence in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company provides a diverse portfolio of pharmaceutical solutions across various therapeutic areas, including oncology, hematology, and immunology, among others.
In addition to its pharmaceutical business, Roche also offers a range of diagnostic solutions, including in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, and infectious diseases. The companys diagnostic portfolio also includes diagnostic instruments and digital health solutions, which are increasingly important in the modern healthcare landscape.
From a financial perspective, Roche has a market capitalization of approximately CHF 208.7 billion, indicating its significant size and market presence. The companys return on equity (RoE) of 67.87% suggests a high level of profitability, driven by its successful pharmaceutical and diagnostic products. Furthermore, Roches forward price-to-earnings (P/E) ratio of 13.25 implies that the companys future earnings growth is expected to be robust, potentially driven by its pipeline of new products and innovations.
Some additional key performance indicators (KPIs) that can provide further insights into Roches performance include its revenue growth rate, research and development (R&D) expenditure as a percentage of sales, and its dividend yield. Roche has historically been a significant player in the R&D landscape, with a strong focus on innovation and a pipeline of new products in various stages of development. The companys dividend yield, which is not disclosed in the provided data, is also an important metric for income-focused investors.
Roches commitment to innovation and R&D is reflected in its significant investments in this area, with a focus on developing new treatments and diagnostic solutions for various diseases. The companys website (https://www.roche.com) provides further information on its products, pipeline, and research initiatives, offering insights into its strategic priorities and growth prospects.
ROG Stock Overview
| Market Cap in USD | 262,351m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
ROG Stock Ratings
| Growth Rating | -11.9% |
| Fundamental | 78.7% |
| Dividend Rating | 57.9% |
| Return 12m vs S&P 500 | -18.8% |
| Analyst Rating | - |
ROG Dividends
| Dividend Yield 12m | 3.71% |
| Yield on Cost 5y | 3.63% |
| Annual Growth 5y | 1.30% |
| Payout Consistency | 100.0% |
| Payout Ratio | 82.6% |
ROG Growth Ratios
| Growth Correlation 3m | -53.1% |
| Growth Correlation 12m | 3.2% |
| Growth Correlation 5y | -46.8% |
| CAGR 5y | -0.49% |
| CAGR/Max DD 5y | -0.01 |
| Sharpe Ratio 12m | 1.91 |
| Alpha | -13.06 |
| Beta | 0.271 |
| Volatility | 18.48% |
| Current Volume | 740.7k |
| Average Volume 20d | 904.3k |
| Stop Loss | 253.1 (-3%) |
| Signal | 0.38 |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (20.05b TTM) > 0 and > 6% of Revenue (6% = 7.28b TTM) |
| FCFTA 0.22 (>2.0%) and ΔFCFTA 8.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 6.70% (prev 7.85%; Δ -1.15pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.37 (>3.0%) and CFO 34.60b > Net Income 20.05b (YES >=105%, WARN >=100%) |
| Net Debt (29.38b) to EBITDA (23.58b) ratio: 1.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (796.3m) change vs 12m ago -0.96% (target <= -2.0% for YES) |
| Gross Margin 73.66% (prev 72.64%; Δ 1.02pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 135.4% (prev 72.02%; Δ 63.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.03 (EBITDA TTM 23.58b / Interest Expense TTM 1.67b) >= 6 (WARN >= 3) |
Altman Z'' 4.11
| (A) 0.09 = (Total Current Assets 35.70b - Total Current Liabilities 27.58b) / Total Assets 94.77b |
| (B) 0.45 = Retained Earnings (Balance) 42.98b / Total Assets 94.77b |
| (C) 0.21 = EBIT TTM 18.43b / Avg Total Assets 89.57b |
| (D) 0.65 = Book Value of Equity 43.09b / Total Liabilities 66.09b |
| Total Rating: 4.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.69
| 1. Piotroski 9.0pt = 4.0 |
| 2. FCF Yield 9.13% = 4.57 |
| 3. FCF Margin 17.56% = 4.39 |
| 4. Debt/Equity 1.06 = 1.97 |
| 5. Debt/Ebitda 1.29 = 1.32 |
| 6. ROIC - WACC 16.55% = 12.50 |
| 7. RoE 67.56% = 2.50 |
| 8. Rev. Trend -58.00% = -2.90 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 13.82% = 0.35 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ROG shares?
Over the past week, the price has changed by -0.57%, over one month by +0.15%, over three months by +0.31% and over the past year by -4.45%.
Is Roche Holding a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ROG is around 248.79 CHF . This means that ROG is currently overvalued and has a potential downside of -4.68%.
Is ROG a buy, sell or hold?
What are the forecasts/targets for the ROG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 298.1 | 14.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 272 | 4.2% |
ROG Fundamental Data Overview
Market Cap CHF = 210.34b (210.34b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 7.55b CHF (last quarter)
P/E Trailing = 22.3785
P/E Forward = 12.9199
P/S = 3.313
P/B = 7.2862
P/EG = 0.6796
Beta = 0.174
Revenue TTM = 121.28b CHF
EBIT TTM = 18.43b CHF
EBITDA TTM = 23.58b CHF
Long Term Debt = 26.46b CHF (from longTermDebt, last quarter)
Short Term Debt = 3.93b CHF (from shortTermDebt, last quarter)
Debt = 30.39b CHF (Calculated: Short Term 3.93b + Long Term 26.46b)
Net Debt = 29.38b CHF (from netDebt column, last fiscal year)
Enterprise Value = 233.18b CHF (210.34b + Debt 30.39b - CCE 7.55b)
Interest Coverage Ratio = 11.03 (Ebit TTM 18.43b / Interest Expense TTM 1.67b)
FCF Yield = 9.13% (FCF TTM 21.30b / Enterprise Value 233.18b)
FCF Margin = 17.56% (FCF TTM 21.30b / Revenue TTM 121.28b)
Net Margin = 16.53% (Net Income TTM 20.05b / Revenue TTM 121.28b)
Gross Margin = 73.66% ((Revenue TTM 121.28b - Cost of Revenue TTM 31.95b) / Revenue TTM)
Tobins Q-Ratio = 5.41 (Enterprise Value 233.18b / Book Value Of Equity 43.09b)
Interest Expense / Debt = 2.05% (Interest Expense 623.0m / Debt 30.39b)
Taxrate = 22.10% (from yearly Income Tax Expense: 2.61b / 11.79b)
NOPAT = 14.36b (EBIT 18.43b * (1 - 22.10%))
Current Ratio = 1.29 (Total Current Assets 35.70b / Total Current Liabilities 27.58b)
Debt / Equity = 1.06 (Debt 30.39b / last Quarter total Stockholder Equity 28.68b)
Debt / EBITDA = 1.29 (Net Debt 29.38b / EBITDA 23.58b)
Debt / FCF = 1.43 (Debt 30.39b / FCF TTM 21.30b)
Total Stockholder Equity = 29.68b (last 4 quarters mean)
RoA = 21.16% (Net Income 20.05b, Total Assets 94.77b )
RoE = 67.56% (Net Income TTM 20.05b / Total Stockholder Equity 29.68b)
RoCE = 32.83% (Ebit 18.43b / (Equity 29.68b + L.T.Debt 26.46b))
RoIC = 22.87% (NOPAT 14.36b / Invested Capital 62.78b)
WACC = 6.33% (E(210.34b)/V(240.73b) * Re(7.01%)) + (D(30.39b)/V(240.73b) * Rd(2.05%) * (1-Tc(0.22)))
Shares Correlation 5-Years: -70.0 | Cagr: -1.83%
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.63% ; FCFE base≈17.46b ; Y1≈17.87b ; Y5≈19.87b
Fair Price DCF = 507.5 (DCF Value 350.00b / Shares Outstanding 689.6m; 5y FCF grow 2.25% → 3.0% )
Revenue Correlation: -58.00 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: 11.74
EPS Correlation: 13.82 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -15.61